FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2113774911> ?p ?o ?g. }

• W2113774911 endingPage "F443" @default.
• W2113774911 startingPage "F442" @default.
• W2113774911 abstract "LETTERS TO THE EDITORReply to Geerling and LoewyAnikó Náray-Fejes-Tóth, and Géza Fejes-TóthAnikó Náray-Fejes-Tóth, and Géza Fejes-TóthPublished Online:01 Jul 2007https://doi.org/10.1152/ajprenal.00211.2007MoreSectionsPDF (43 KB)Download PDF ToolsExport citationAdd to favoritesGet permissionsTrack citations ShareShare onFacebookTwitterLinkedInEmailWeChat reply: The main purpose of generating a mouse strain with 11β-hydroxysteroid dehydrogenase-2 (11β-HSD2) promoter-driven Cre expression was to facilitate in vivo studies aimed at assessing the role of aldosterone-regulated genes in electrolyte balance and cardiovascular function. Aldosterone responsiveness is restricted to cells that simultaneously express both the mineralocorticoid receptor (MR) and 11-HSD2 in physiologically relevant amounts. Consequently, in an ideal deleter strain for such studies, Cre activity should be restricted both spatially and temporally to a pattern that corresponds to the overlap between the expression domains of these two genes. Since regulatory elements that recapitulate such a pattern have not yet been identified (and may not even exist), a “second best” approach is to constrain recombinase activity to a pattern that conforms to the expression profile of either the MR or the 11-HSD2 gene. An unavoidable consequence of this compromise is that recombination may also occur in cells that are not aldosterone responsive since the two genes have overlapping but distinct expression domains. Consequently, with a Cre construct driven by MR regulatory elements, recombination is also expected to take place in tissues that are normally not regulated by aldosterone, such as the hippocampus (and possibly at other sites, given the relatively widespread expression of the MR) (1, 9). Conversely, if Cre expression is placed under the control of the 11-HSD2 gene, besides aldosterone target cells, one should anticipate somatic mutagenesis to occur wherever and whenever the 11-HSD2 gene is active. Thus one of the goals of our study was to map such sites of recombination, so that the utility and limitations of this new model can be considered. To facilitate the interpretation of these findings, we emphasized in our Discussion that “Since in our studies iCre driven by 11-HSD2 is already active during embryonic life, these findings might reflect 11-HSD2 expression during development” and that “X-gal staining can represent 11-HSD2 expression at any time during development, since the 11-HSD2-driven iCre activity results in permanent excision of the stop codon from the β-galactosidase gene present in the ROSA26 reporter mouse” (8).Besides providing aldosterone specificity to mineralocorticoid target cells, 11-HSD2 also seems to be employed to limit glucocorticoid activity at other sites, such as certain regions of the developing brain (2, 5, 7, 10) and some reproductive organs (3, 13). Thus it should come as no surprise that these sites and/or their derivatives also became LacZ positive in our studies, since Cre-mediated recombination by design is irreversible. The expression of 11-HSD2 at several of these loci, including the cerebellum and thalamus, is well documented in the literature (2, 5, 7, 10) while activity at other sites like the cartilage was unexpected.The issue of 11-HSD2 expression in the brain was not the main focus of our study. This topic is linked to a substantial but somewhat confusing literature. Our selection of references was guided by their relevance to our findings and by space limitations and not by an attempt “to disregard prior data that were not consistent with (our) interpretation” as Geerling and Loewy (6a) assert.Initial as well as some more recent studies failed to detect 11-HSD2 mRNA in the CNS (4, 11, 12) while others reported relatively widespread distribution especially during the pre- and perinatal period (2, 5, 7, 10). The lack of consistency is likely related to one of the few observations on which there seems to be a consensus; i.e., that compared with classic MR target sites, 11-HSD2 expression in the brain is quite low, which makes an evaluation of its distribution in the central nervous system challenging. This is particularly true for immunohistochemistry, especially when the antibody used recognizes multiple proteins on Western blots and if specific staining is demarcated from spurious binding by a less than a twofold difference in antibody concentration (6). Furthermore, even a clear-cut demonstration of 11-HSD2 protein does not guarantee that its presence is physiologically relevant, and conversely, levels that fall below the detection limit may still mediate a biological function. In this context, it is interesting to note that targeted disruption of the 11-HSD2 gene leads to abnormal cerebellar morphology (7) and that 11-HSD2 activity in the paraventicular nucleus also seems to be functionally important (14), even though no 11-HSD2 protein was detected at these sites by immunohistochemistry (6).REFERENCES1 Bookout AL, Jeong Y, Downes M, Yu RT, Evans RM, Mangelsdorf DJ. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell 126: 789–799, 2006.Crossref | PubMed | ISI | Google Scholar2 Brown RW, Diaz R, Robson AC, Kotelevtsev YV, Mullins JJ, Kaufman MH, Seckl JR. The ontogeny of 11 beta-hydroxysteroid dehydrogenase type 2 and mineralocorticoid receptor gene expression reveal intricate control of glucocorticoid action in development. Endocrinology 137: 794–797, 1996.Crossref | PubMed | ISI | Google Scholar3 Burton PJ, Krozowski ZS, Waddell BJ. Immunolocalization of 11beta-hydroxysteroid dehydrogenase types 1 and 2 in rat uterus: variation across the estrous cycle and regulation by estrogen and progesterone. Endocrinology 139: 376–382, 1998.Crossref | PubMed | ISI | Google Scholar4 Cole TJ. Cloning of the mouse 11 beta-hydroxysteroid dehydrogenase type 2 gene: tissue specific expression and localization in distal convoluted tubules and collecting ducts of the kidney. Endocrinology 136: 4693–4696, 1995.Crossref | PubMed | ISI | Google Scholar5 Diaz R, Brown RW, Seckl JR. Distinct ontogeny of glucocorticoid and mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase types I and II mRNAs in the fetal rat brain suggest a complex control of glucocorticoid actions. J Neurosci 18: 2570–2580, 1998.Crossref | PubMed | ISI | Google Scholar6 Geerling JC, Kawata M, Loewy AD. Aldosterone-sensitive neurons in the rat central nervous system. J Comp Neurol 494: 515–527, 2006.Crossref | PubMed | ISI | Google Scholar6a Geerling JC, Loewy AD. Am J Physiol Renal Physiol; doi:10.1152/ajprenal.00517.2006.Google Scholar7 Holmes MC, Sangra M, French KL, Whittle IR, Paterson J, Mullins JJ, Seckl JR. 11beta-Hydroxysteroid dehydrogenase type 2 protects the neonatal cerebellum from deleterious effects of glucocorticoids. Neuroscience 137: 865–873, 2006.Crossref | PubMed | ISI | Google Scholar8 Naray-Fejes-Toth A, Fejes-Toth G. Novel mouse strain with Cre recombinase in 11β-hydroxysteroid dehydrogenase-2-expressing cells. Am J Physiol Renal Physiol 292: F486–F494, 2007.Link | ISI | Google Scholar9 NURSA. Nuclear Receptor Signaling Atlas. http://www.NURSA.nursa.org/qpcr.cfm?datatype=tissue&dataId=1&expType=mol&dataset=131&datanumber=1.Google Scholar10 Robson AC, Leckie CM, Seckl JR, Holmes MC. 11 Beta-hydroxysteroid dehydrogenase type 2 in the postnatal and adult rat brain. Brain Res Mol Brain Res 61: 1–10, 1998.Crossref | PubMed | Google Scholar11 Roland BL, Krozowski ZS, Funder JW. Glucocorticoid receptor, mineralocorticoid receptors, 11 beta-hydroxysteroid dehydrogenase-1 and -2 expression in rat brain and kidney: in situ studies. Mol Cell Endocrinol 111: R1–7, 1995.Crossref | PubMed | ISI | Google Scholar12 Thompson A, Han VK, Yang K. Differential expression of 11beta-hydroxysteroid dehydrogenase types 1 and 2 mRNA and glucocorticoid receptor protein during mouse embryonic development. J Steroid Biochem Mol Biol 88: 367–375, 2004.Crossref | PubMed | ISI | Google Scholar13 Waddell BJ, Hisheh S, Krozowski ZS, Burton PJ. Localization of 11beta-hydroxysteroid dehydrogenase types 1 and 2 in the male reproductive tract. Endocrinology 144: 3101–3106, 2003.Crossref | PubMed | ISI | Google Scholar14 Zhang ZH, Kang YM, Yu Y, Wei SG, Schmidt TJ, Johnson AK, Felder RB. 11beta-hydroxysteroid dehydrogenase type 2 activity in hypothalamic paraventricular nucleus modulates sympathetic excitation. Hypertension 48: 127–133, 2006.Crossref | PubMed | ISI | Google ScholarAUTHOR NOTESAddress for reprint requests and other correspondence: A. Náray-Fijes-Tóth, Dept. of Physiology, Dartmouth Medical School, Lebanon, NH 03756-0001 (e-mail: [email protected]) Download PDF Previous Back to Top FiguresReferencesRelatedInformation More from this issue > Volume 293Issue 1July 2007Pages F442-F443 Copyright & PermissionsCopyright © 2007 the American Physiological Societyhttps://doi.org/10.1152/ajprenal.00211.2007History Published online 1 July 2007 Published in print 1 July 2007 Metrics" @default.
• W2113774911 created "2016-06-24" @default.
• W2113774911 creator A5001390749 @default.
• W2113774911 creator A5005034773 @default.
• W2113774911 date "2007-07-01" @default.
• W2113774911 modified "2023-10-17" @default.
• W2113774911 title "Reply to Geerling and Loewy" @default.
• W2113774911 cites W1970205218 @default.
• W2113774911 cites W1979636816 @default.
• W2113774911 cites W2011896070 @default.
• W2113774911 cites W2057626289 @default.
• W2113774911 cites W2081276639 @default.
• W2113774911 cites W2094502922 @default.
• W2113774911 cites W2100008493 @default.
• W2113774911 cites W2114792114 @default.
• W2113774911 cites W2131636354 @default.
• W2113774911 cites W2151614193 @default.
• W2113774911 cites W2153023692 @default.
• W2113774911 cites W2156281856 @default.
• W2113774911 cites W2171171251 @default.
• W2113774911 cites W4319292986 @default.
• W2113774911 doi "https://doi.org/10.1152/ajprenal.00211.2007" @default.
• W2113774911 hasPublicationYear "2007" @default.
• W2113774911 type Work @default.
• W2113774911 sameAs 2113774911 @default.
• W2113774911 citedByCount "0" @default.
• W2113774911 crossrefType "journal-article" @default.
• W2113774911 hasAuthorship W2113774911A5001390749 @default.
• W2113774911 hasAuthorship W2113774911A5005034773 @default.
• W2113774911 hasConcept C11171543 @default.
• W2113774911 hasConcept C15744967 @default.
• W2113774911 hasConceptScore W2113774911C11171543 @default.
• W2113774911 hasConceptScore W2113774911C15744967 @default.
• W2113774911 hasIssue "1" @default.
• W2113774911 hasLocation W21137749111 @default.
• W2113774911 hasOpenAccess W2113774911 @default.
• W2113774911 hasPrimaryLocation W21137749111 @default.
• W2113774911 hasRelatedWork W1884192967 @default.
• W2113774911 hasRelatedWork W1969312240 @default.
• W2113774911 hasRelatedWork W1970739065 @default.
• W2113774911 hasRelatedWork W2036405309 @default.
• W2113774911 hasRelatedWork W2040661167 @default.
• W2113774911 hasRelatedWork W2063369216 @default.
• W2113774911 hasRelatedWork W2091657769 @default.
• W2113774911 hasRelatedWork W2118933882 @default.
• W2113774911 hasRelatedWork W2315978648 @default.
• W2113774911 hasRelatedWork W3140514088 @default.
• W2113774911 hasVolume "293" @default.
• W2113774911 isParatext "false" @default.
• W2113774911 isRetracted "false" @default.
• W2113774911 magId "2113774911" @default.
• W2113774911 workType "article" @default.